Regulatory GSK eyes October FDA verdict on chronic hep B drug PharmaphorumGSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.Infectious DiseaseRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Merck KGaA and Remepy join forces to develop combo drug-digital therapiesNext: Coultreon banks $125M to support testing of former Galapagos immune drug Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
